Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Women undergoing breast cancer treatment are not getting recommended follow-up heart scans

Women undergoing breast cancer treatment are not getting recommended follow-up heart scans

Immunotherapy with experimental monoclonal antibody could reduce neuroblastoma tumors

Immunotherapy with experimental monoclonal antibody could reduce neuroblastoma tumors

Additional drug treatment options to prevent migraine may offer hope to sufferers

Additional drug treatment options to prevent migraine may offer hope to sufferers

Oncologists to present latest research findings at ASCO annual meeting

Oncologists to present latest research findings at ASCO annual meeting

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

Phase I study of triple drug combination shows promise in multiple myeloma patients

Phase I study of triple drug combination shows promise in multiple myeloma patients

New lab blood test may help identify HELLP syndrome in pregnant women

New lab blood test may help identify HELLP syndrome in pregnant women

Understanding antibody transport mechanisms in the brain

Understanding antibody transport mechanisms in the brain

Mepolizumab has no hint of added benefit in eosinophilic asthma

Mepolizumab has no hint of added benefit in eosinophilic asthma

Rab inhibition may be a promising antimyeloma strategy

Rab inhibition may be a promising antimyeloma strategy

First-ever nivolumab drug trial for rare, malignant SCCA shows positive results

First-ever nivolumab drug trial for rare, malignant SCCA shows positive results

Manipulation of signals in nervous system can enhance recovery after traumatic injury

Manipulation of signals in nervous system can enhance recovery after traumatic injury

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Ludwig, CRI launch Phase 1/2 trial of combination immunotherapy for advanced ovarian cancer

Structure-based approach could lead to effective HIV vaccine

Structure-based approach could lead to effective HIV vaccine

SCIEX and QPS Holdings enter collaboration to establish the BioBA solution for bioanalysis of biologics

SCIEX and QPS Holdings enter collaboration to establish the BioBA solution for bioanalysis of biologics

CHMP recommends conditional marketing authorisation for Janssen’s daratumumab

CHMP recommends conditional marketing authorisation for Janssen’s daratumumab

Researchers develop novel vaccine strategy to protect against Chikungunya virus

Researchers develop novel vaccine strategy to protect against Chikungunya virus

High out-of-pocket costs linked to lower use of specialty drugs

High out-of-pocket costs linked to lower use of specialty drugs

Cinqair (reslizumab) approved for treatment of severe asthma

Cinqair (reslizumab) approved for treatment of severe asthma

Antibodies given within one day of SHIV exposure can clear the virus

Antibodies given within one day of SHIV exposure can clear the virus

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.